RxDoctor Payments Data

Francis Giles

Hematology & Oncology · San Antonio, TXNPI 1750480950

Payments from drug & device makers

$452,672in general payments, 2019–2025

Across 35 payments — averaging $12,933 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Morphosys, US Inc.$419K
  • AstraZeneca$17K
  • Morphosys AG$10K
  • Pfizer$7K
$26,950in research payments, 2019–2025

Across 26 payments — averaging $1036.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$26K
  • Novartis$1K

What the payments were for

  • Consulting fees$425,80098%
  • Speaking & faculty fees$7,3402%
  • Travel & lodging$2,8071%

General payments by program year

19
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Morphosys, US Inc.19$418,607
AstraZeneca2$16,724
Morphosys AG1$10,000
Pfizer13$7,340

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$452,672 in reported general payments places this provider in the 80th percentile of 838 hematology & oncology providers in Texas.

See all hematology & oncology providers in Texas

Other hematology & oncology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →